Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFOXIRI Combined With Lateral Lymph Node Dissection in Rectal Cancer
NCT06048146Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of FOLFIRINOX in rectal cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3 year disease free survival. Started Oct 2022; status: completed.
02
Drugs
FOLFIRINOX
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06048146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048146.